Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma

Clin Lung Cancer. 2021 May;22(3):e366-e370. doi: 10.1016/j.cllc.2020.05.026. Epub 2020 Jun 2.

Authors

Shuai Wang¹, Xuan Wu¹, Jiuzhou Zhao², Haiyang Chen¹, Zhe Zhang¹, Mingyue Wang¹, Cong Xu¹, Yongsen Wang², Lili Wang¹, Zhen He¹, Qiming Wang³

Affiliations

¹ Department of Internal Medicine, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, PR China.
² Department of Molecular Pathology, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, PR China.
³ Department of Internal Medicine, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, PR China. Electronic address: qimingwang1006@126.com.

PMID: 32651063
DOI: 10.1016/j.cllc.2020.05.026

No abstract available

Keywords: Crizotinib; Generation sequencin; Lung large-cell neuroendocrine carcinoma; PLB1-ALK; Sensitivity.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anaplastic Lymphoma Kinase / genetics
Carcinoma, Large Cell / drug therapy*
Carcinoma, Large Cell / genetics
Carcinoma, Large Cell / pathology
Carcinoma, Neuroendocrine / drug therapy*
Carcinoma, Neuroendocrine / genetics
Carcinoma, Neuroendocrine / pathology
Crizotinib / pharmacology*
Gene Rearrangement
High-Throughput Nucleotide Sequencing
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Lysophospholipase / genetics
Male
Protein Kinase Inhibitors / pharmacology

Substances

Protein Kinase Inhibitors
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
Lysophospholipase